{"id":"W4296696831","doi":"10.1136/ard-2022-222259","title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Medical Research Council; Manchester Biomedical Research Centre; St. Jude Medical; Genentech; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Regado Biosciences; Medicines Company; Acceleron; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; University of North Carolina at Chapel Hill; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Duke Clinical Research Institute; Eisai; Cytokinetics; Bristol-Myers Squibb; Cleveland Clinic; Belvoir Media Group; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Gilead Sciences; HLS Therapeutics; Gedeon Richter; GlaxoSmithKline; National Institute for Health and Care Research; CSL Behring; Eli Lilly and Company; Amgen; Moderna; Pfizer; Sanofi; American Heart Association","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Disease; Post-hoc analysis; Internal medicine; Adverse effect; Risk factor; Tumor necrosis factor alpha; Arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003606887,0.001136667,0.003237423,0.0003798425,0.00027808,0.001062587,0.0005818593,0.0005530638,0.001927456],"category_scores_gemma":[0.003250731,0.0004289311,0.006231699,0.0004047999,0.0003827158,0.0006639026,0.0006291877,0.001385176,0.0001577729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004120268,"about_ca_system_score_gemma":0.000757669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001301288,"about_ca_topic_score_gemma":0.00204174,"domain_scores_codex":[0.9978781,0.001150812,0.0001267187,0.000368362,0.0001806498,0.0002953979],"domain_scores_gemma":[0.9972457,0.001516451,0.0004159079,0.0002774555,0.0001176082,0.0004269565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5397376,0.001774039,0.3918026,0.0007495168,0.03246573,0.0006843756,0.0002544414,0.001943142,0.004315418,0.0001141345,0.001262746,0.02489626],"study_design_scores_gemma":[0.03414334,0.1273335,0.7877988,0.0001239006,0.03086134,0.001006347,0.0005250854,0.01273215,0.00325035,0.0003163567,0.001774774,0.0001340615],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984061,0.0006580041,0.000253095,0.00003862668,0.00003074179,0.0000626008,0.0002794009,0.000009775858,0.0002617192],"genre_scores_gemma":[0.9984249,0.0001893483,0.0002812387,0.0000479245,0.0000660388,0.0001025501,0.0004437648,0.000006280873,0.0004380539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003606887,"threshold_uncertainty_score":0.01907527,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01861963224089894,"score_gpt":0.2328494525307303,"score_spread":0.2142298202898314,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}